Linden LLC

Evolution Research Group Acquires Finger Lakes Clinical Research

April 1, 2019 | For Immediate Release

New Providence, NJ (April 1, 2019) – Evolution Research Group (“ERG”), a leading independent clinical research site business with a focus in neuroscience and other special populations, announced today the acquisition of Rochester, NY-based Finger Lakes Clinical Research (“FLCR”), a clinical research facility specializing in central nervous system trials for children and adults.

Founded and directed by Principal Investigator Sarah Atkinson, MD, FLCR has conducted trials across a broad range of illnesses, including anxiety disorders, ADHD, depression, bipolar disorder, schizophrenia and other mental illnesses since its founding in 2002. “We are very excited to welcome Dr. Atkinson and FLCR to the ERG family,” said Lori Wright, CEO of ERG. “The addition of FLCR expands ERG’s geographic capabilities in both adult and pediatric outpatient trials and further enhances ERG’s growing service offerings to our clients.” Dr. Atkinson added, “My staff and I are delighted to be joining ERG. Its excellent reputation, high quality standards, clinical expertise, and strong business development capabilities, make ERG the ideal partner for FLCR in this next chapter of our growth.”

Michael Farah, Chairman of ERG and Partner at Linden Capital Partners, added, “Dr. Atkinson is a highly regarded Principal Investigator who has built a high quality and incredibly successful practice that is complementary to ERG. FLCR expands ERG’s footprint in growing psychiatric therapeutic areas and provides additional diversification which will allow us to further service our world-wide clients to develop important new therapies.”

Honigman LLP and Kirkland & Ellis LLP served as legal advisors to ERG.

About Evolution Research Group
ERG is a leading independent clinical research site business serving pharmaceutical companies and CROs, with a focus in neuroscience and other special populations. The Company is comprised of 21 highly experienced and quality-focused sites (10 wholly-owned and 11 affiliated), with over 40 principal investigators, supported by industry-leading clinical operations and business development teams. For more information, please visit

About Linden Capital Partners
Linden Capital Partners is a Chicago-based private equity firm focused exclusively on investing in the healthcare industry. Linden’s strategy is based upon three elements: i) healthcare specialization, ii) integrated private equity and operating expertise, and iii) strategic relationships with large corporations. Linden invests in middle market platforms across the medical products, specialty distribution, pharmaceutical, and services segments of healthcare. For more information, please visit